Achieve Life Sciences Inc
NASDAQ:ACHV
Intrinsic Value
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. [ Read More ]
The intrinsic value of one
ACHV
stock under the Base Case scenario is
10.66
USD.
Compared to the current market price of 5.32 USD,
Achieve Life Sciences Inc
is
Undervalued by 50%.
Achieve Life Sciences Inc's market capitalization is 182.2m USD.
ACHV stock price is 5.32 USD.
ACHV stock price (5.32 USD) is 50% less than its Intrinsic Value (10.66 USD).
ACHV. Open Relative Valuation
ACHV has upside potential of 262% compared to the average analyst price target.
Open Wall St Estimates
ACHV has negative Free Cash Flow for the last twelve months.
ACHV has negative Operating Income for the last twelve months.
ACHV has negative Net Income for the last twelve months.
ACHV's ROE (Return on Equity) has significantly decreased in the last 3 years from -86% to -110%, and is approaching profitability.
ACHV's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -503% to -763%, and is approaching profitability.
ACHV's ROE (Return on Equity) for the past 12 months is negative and is equal to -110%.
ACHV's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -763%.
ACHV's short-term assets (68m USD) exceed its short-term liabilties (21m USD).
ACHV's long-term assets (70m USD) exceed its long-term liabilties (21m USD).
ACHV has negative three-year average ROE (Return on Equity): -327%. The company is not efficient at transforming stockholders' equity into net income.
ACHV has negative three-year average ROIC (Return on Invested Capital): -864%. The company is not efficient at using invested capital to generate operating income.
ACHV's D/E (Debt to Equity) is very low and is equal to 0.
ACHV's Altman Z-Score is very low and is equal to -0.39.
Valuation Backtest
Achieve Life Sciences Inc
Run backtest to discover the historical profit from buying and selling
ACHV
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Achieve Life Sciences Inc
Balance Sheet Decomposition
Achieve Life Sciences Inc
| Current Assets | 67.7m |
| Cash & Short-Term Investments | 66.4m |
| Other Current Assets | 1.3m |
| Non-Current Assets | 2.3m |
| PP&E | 51k |
| Intangibles | 2.2m |
| Other Non-Current Assets | 94k |
| Current Liabilities | 20.6m |
| Accounts Payable | 373k |
| Accrued Liabilities | 2.5m |
| Other Current Liabilities | 17.7m |
Earnings Waterfall
Achieve Life Sciences Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-24.6m
USD
|
|
Operating Income
|
-24.6m
USD
|
|
Other Expenses
|
-2.7m
USD
|
|
Net Income
|
-27.3m
USD
|
Free Cash Flow Analysis
Achieve Life Sciences Inc
| USD | |
| Free Cash Flow | USD |
ACHV Profitability Score
Profitability Due Diligence
Achieve Life Sciences Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Achieve Life Sciences Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ACHV Solvency Score
Solvency Due Diligence
Achieve Life Sciences Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Achieve Life Sciences Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACHV Price Targets Summary
Achieve Life Sciences Inc
According to Wall Street analysts, the average 1-year price target for
ACHV
is 19.25 USD
with a low forecast of 10.1 USD and a high forecast of 31.5 USD.
Ownership
ACHV Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ACHV Price
Achieve Life Sciences Inc
| Average Annual Return | -43.86% |
| Standard Deviation of Annual Returns | 41.69% |
| Max Drawdown | -97% |
| Market Capitalization | 182.2m USD |
| Shares Outstanding | 34 341 300 |
| Percentage of Shares Shorted | 2.85% |
Company Profile
Achieve Life Sciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 16 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The firm is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).
Contact
IPO
Employees
Officers
The intrinsic value of one
ACHV
stock under the Base Case scenario is
10.66
USD.
Compared to the current market price of 5.32 USD,
Achieve Life Sciences Inc
is
Undervalued by 50%.
You don't have any saved screeners yet
